VANCOUVER, June 20, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is
pleased to announce the voting results from its Annual General
Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on June 20, 2019. The total number of shares
represented by shareholders present in person and by proxy at the
meeting was 32,141,666 million representing 15.47% of Sirona's
issued and outstanding Common Shares.
All of the matters put forward before shareholders for
consideration and approval as set out in the Company's Management
Information Circular dated 22nd of May, 2019, were
approved by the requisite majority of votes cast at the Meeting.
The details of the voting results for the election of directors are
set out below:
Nominee
|
# Votes
for
|
% Votes
for
|
Géraldine
Deliencourt-Godefroy
|
31,845,566
|
99.1
|
Howard
Verrico
|
31,595,566
|
98.3
|
Christopher
Hopton
|
31,595,566
|
98.3
|
Alex
Marazzi
|
31,595,566
|
98.3
|
Jason Tian
|
Appointed
director
|
The shareholders also approved: (i) fixing of the number of
directors of the Company at five; (ii) appointing MNP LLP,
Chartered Accountants, as the Company's auditor for the ensuing
year and authorizing the directors to set the auditor's
remuneration; and (iii) confirming and approving the Company's
existing stock option plan.
The Company will file a report of voting results on all
resolutions voted on at the Meeting on www.sedar.com shortly.
CEO AGM Update
Dear Shareholders,
I'd like to take this opportunity to thank you for the continued
support of Sirona. It is of great satisfaction to have over 98% of
votes cast to support the current management team. This has been an
exciting breakthrough year and we are grateful that you have
remained on board with us, sharing our successes of Sirona's novel
platform technology.
Rodan + Fields have completed extensive due diligence on
TFC-1067. This included both the data package provided by Sirona as
well as their independent research and analysis on the compound.
Rodan + Fields, the No. 1 skincare brand in North America in terms of total
sales, are now moving our novel skin lightener towards full
commercialization. The anticipated definitive agreement with
Rodan + Fields has enormous value to Sirona, far beyond
North America.
It is particularly important for our European shareholders to
understand that Rodan + Fields utilizes approximately 300,000
consultants to sell products. Their skincare starter kits are aimed
at reducing the appearance of lines, dark spots, and acne in adult
women. Rodan + Fields are a perfect fit for Sirona and vice versa.
We are confident Rodan + Fields will deliver industry leading
products incorporating Sirona's skin lightener TFC-1067.
After the heavy lifting is done and while we work together with
Rodan + Fields through the stages of commercialization, further
partners for other sales channels and regions will beat a path to
our door. The discussions with our potential TFC-1067 partner for
China are also nearing
completion.
We anticipate more exciting news from China as Wanbang's management meets to approve
the release of information. We are also in advanced discussions on
a large new project with a global corporation that we hope to share
with you in Q4/2019.
The current market capitalization for Sirona Biochem has
increased substantially thanks to positive company developments as
well as growing shareholder support. Sirona's management has now
decided to establish a shareholder rights plan ("Poison Pill") and
has asked our legal counsel to take the necessary steps to put this
in place.
The adoption of the Poison Pill is intended to protect Sirona
Biochem and its shareholders from the actions of third parties that
the Board of Directors determines are not in the best interests of
Sirona Biochem and its shareholders, and to enable all shareholders
to realize the long-term value of their investment in Sirona
Biochem.
The Board of Directors believes that the Poison Pill will ensure
that the Board of Directors remains in the best position to
discharge its fiduciary duties to Sirona Biochem and its
shareholders. The Poison Pill is not intended to interfere with any
sale, merger, tender or exchange offer, or other business
combination approved by the Board of Directors. Nor does the Poison
Pill prevent the Sirona Biochem Board of Directors from considering
any offer that it deems to be in the best interest of Sirona
Biochem's shareholders.
We have exciting times ahead of us.
Sincerely,
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.